Muscle-Targeting Antibody-Oligonucleotide Complexes for DM1 Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are ineffective for treating myotonic dystrophy type 1 (DM1), a dominantly inherited genetic disease characterized by muscle degeneration, insulin resistance, cardiac arrhythmia, and neurological abnormalities, due to the lack of targeted delivery of molecular payloads to muscle cells.
Innovation Solution
Development of muscle-targeting complexes comprising antibodies covalently linked to molecular payloads, such as oligonucleotides, that specifically bind to muscle cells via the transferrin receptor, facilitating receptor-mediated internalization and subsequent release within cells to inhibit mutant DMPK expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If molecular payloads are delivered to muscle cells using non-specific delivery methods, then the payloads can reach muscle cells, but off-target toxicity occurs and therapeutic effectiveness is reduced
Solution Approach 1:
The patent uses the transferrin receptor as an intermediary mediator to deliver molecular payloads specifically to muscle cells. The anti-transferrin receptor antibody binds to the receptor on muscle cell surfaces, serving as a bridge that directs the payload (oligonucleotide) specifically to the target cells, thereby avoiding off-target toxicity while maintaining therapeutic effectiveness
Solution Approach 2:
The invention applies local quality by creating complexes with specific properties tailored for muscle cell delivery. The anti-transferrin receptor antibody provides muscle-specific targeting capability, while the oligonucleotide payload provides disease-specific inhibition of DMPK expression. This localized specificity ensures therapeutic action is concentrated where needed (in muscle cells expressing the transferrin receptor) without affecting other tissues
2Ease of operation
If conventional therapies are used for myotonic dystrophy type 1, then treatment can be administered, but the therapies are ineffective due to lack of targeted delivery to muscle cells
Solution Approach 1:
The patent merges two distinct functional components into a single therapeutic complex: the anti-transferrin receptor antibody (providing targeting function) and the oligonucleotide payload (providing therapeutic function). This combination allows the treatment to be administered as a single agent that simultaneously achieves both targeted delivery to muscle cells and effective inhibition of mutant DMPK expression, resolving the contradiction between ease of administration and therapeutic effectiveness
3Object-affected harmful factors
If muscle-targeting complexes are developed with high specificity, then off-target toxicity is minimized, but the complexity of the treatment increases
Solution Approach 1:
The invention creates a composite therapeutic complex consisting of the anti-transferrin receptor antibody and the oligonucleotide payload. This composite structure integrates the targeting functionality of the antibody with the therapeutic functionality of the oligonucleotide, achieving high specificity for muscle cells while maintaining a relatively simple administration protocol. The composite nature allows both functions to work synergistically without requiring separate administration steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complexes effectively reduce DMPK expression in muscle cells, demonstrating potential therapeutic benefits for treating myotonic dystrophy by selectively targeting and reducing disease-associated RNA levels in muscle tissues while minimizing off-target toxicity.
Implementation Method 1
the complexes are taken up into the cells via a receptor mediated internalization
Data Source
AI summary
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.